Moderna (MRNA) Change in Receivables (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Receivables data on file, last reported at -$114.0 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 59.29% year-over-year to -$114.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 116.95% increase from a year earlier, with the FY2025 full-year figure at -$156.0 million, up 70.79% from the prior year.
• Change in Receivables for Q1 2026 stood at -$114.0 million, up from -$859.0 million in the prior quarter.
• Over the last five years, Change in Receivables for MRNA reached as high as $1.6 billion in Q3 2023 and fell as low as -$1.3 billion in Q4 2022.
• Historically, Change in Receivables has averaged -$181.6 million across 5 years, with a median of -$272.0 million in 2023.
• On a YoY basis, Change in Receivables climbed as much as 40750.0% in 2023 and fell as far as 27100.0% in 2023.
• Year by year, Change in Receivables stood at -$1.3 billion in 2022, then climbed by 25.65% to -$974.0 million in 2023, then fell by 23.82% to -$1.2 billion in 2024, then grew by 28.77% to -$859.0 million in 2025, then jumped by 86.73% to -$114.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$114.0 million in Q1 2026, -$859.0 million in Q4 2025, and $1.0 billion in Q3 2025.